Precipio, Inc. will host its Q3-2025 corporate update call on November 17, 2025, at 5:00 PM ET.
Quiver AI Summary
Precipio, Inc., a specialty cancer diagnostics company, announced it will hold its Q3-2025 corporate update call on November 17, 2025, at 5:00 PM ET, to discuss its current core business updates. Interested participants can join the call by dialing 800.717.1738 and may submit questions in advance via email. A replay will be available 24 hours post-call on the company’s investors page. Precipio is dedicated to improving cancer diagnostic accuracy, aiming to address misdiagnoses through innovative products and services. The press release also emphasizes the company's commitment to providing updated information regularly on its website and social media platforms.
Potential Positives
- Precipio, Inc. is hosting a Q3-2025 corporate update call, providing an opportunity for transparency and direct communication with investors.
- The call will include updates on the company's core businesses, indicating ongoing development and potential growth areas.
- Precipio emphasizes its commitment to addressing cancer misdiagnosis through innovative diagnostic products and services, which could enhance its reputation and market position in healthcare biotechnology.
- The availability of a replay of the call and the invitation for questions show Precipio's dedication to investor engagement and transparency.
Potential Negatives
- The press release includes a disclaimer about forward-looking statements, indicating uncertainty about future performance and potential risks, which may lead to investor skepticism.
- No specific updates on the company's performance or any significant achievements are mentioned, which could suggest a lack of progress or clarity about the company's future direction.
- The reliance on external communication methods such as social media to convey material information may raise concerns about the accessibility and reliability of information for investors.
FAQ
When is Precipio's Q3-2025 corporate update call?
Precipio's Q3-2025 corporate update call is on November 17th, 2025 at 5:00 PM ET.
How can I access the Precipio conference call?
You can access the Precipio conference call by calling 800.717.1738 and asking for the Precipio conference call.
Can I submit questions for the Precipio call in advance?
Yes, you can submit questions in advance by emailing [email protected].
Where can I find the replay of the conference call?
The replay of the call will be available on Precipio's Investors page approximately 24 hours after the call.
What is Precipio's mission in cancer diagnostics?
Precipio aims to reduce cancer misdiagnoses by developing diagnostic products and services that improve accuracy and outcomes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PRPO Insider Trading Activity
$PRPO insiders have traded $PRPO stock on the open market 9 times in the past 6 months. Of those trades, 8 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $PRPO stock by insiders over the last 6 months:
- RICHARD A SANDBERG has made 8 purchases buying 15,000 shares for an estimated $135,981 and 0 sales.
- KATHLEEN LAPORTE sold 6,152 shares for an estimated $123,409
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PRPO Hedge Fund Activity
We have seen 6 institutional investors add shares of $PRPO stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMH EQUITY LTD added 103,210 shares (+370.1%) to their portfolio in Q3 2025, for an estimated $1,836,105
- RENAISSANCE TECHNOLOGIES LLC removed 10,700 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $118,127
- UBS GROUP AG added 675 shares (+68.9%) to their portfolio in Q2 2025, for an estimated $7,451
- TOWER RESEARCH CAPITAL LLC (TRC) removed 656 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $7,242
- GEODE CAPITAL MANAGEMENT, LLC added 122 shares (+0.8%) to their portfolio in Q2 2025, for an estimated $1,346
- OSAIC HOLDINGS, INC. added 37 shares (+50.7%) to their portfolio in Q2 2025, for an estimated $408
- ALLWORTH FINANCIAL LP added 3 shares (+inf%) to their portfolio in Q2 2025, for an estimated $33
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW HAVEN, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q3-2025 corporate update call on November 17 th , 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses.
The conference call may be accessed by calling 800.717.1738. All callers should ask for the Precipio conference call.
Listeners interested in submitting questions in advance should email their questions to [email protected] and management will do its best to address those questions during the call.
A replay of the call will be available approximately 24 hours after the call and may be accessed via the Investors page on Precipio's website, https://www.precipiodx.com/investors/ .
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.
Availability of Other Information About Precipio
For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) ( @PrecipioDx ) and LinkedIn (Precipio) and on Facebook . Investors and others should note that we communicate with our investors and the public using our company website ( https://www.precipiodx.com ), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing.
Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date
subsequent to the date of this press release.